

# Guido Grassi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8101607/publications.pdf>

Version: 2024-02-01

490  
papers

41,041  
citations

6254

80  
h-index

2747

192  
g-index

497  
all docs

497  
docs citations

497  
times ranked

30327  
citing authors

#	ARTICLE	IF	CITATIONS
1	Relationships between sympathetic markers and heart rate thresholds for cardiovascular risk in chronic heart failure. <i>Clinical Research in Cardiology</i> , 2023, 112, 59-67.	3.3	4
2	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1501-1509.	1.8	9
3	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. <i>Journal of Nephrology</i> , 2022, 35, 211-221.	2.0	34
4	Blood pressure variability correlates with right ventricular strain in women with gestational hypertension and preeclampsia. <i>Journal of Human Hypertension</i> , 2022, 36, 826-832.	2.2	3
5	Central and peripheral sympathetic activation in heart failure. <i>Cardiovascular Research</i> , 2022, 118, 1857-1871.	3.8	20
6	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. <i>Journal of Human Hypertension</i> , 2022, 36, 976-982.	2.2	20
7	Left ventricular global longitudinal strain in secondary hypertension: A meta-analysis of echocardiographic studies. <i>European Journal of Internal Medicine</i> , 2022, 96, 81-89.	2.2	4
8	Obstructive Sleep Apnea, CPAP and Arterial Hypertension: A Cardiologist's View Point. <i>Archivos De Bronconeumologia</i> , 2022, 58, 461-462.	0.8	12
9	Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 365-371.	1.6	42
10	Sleep Apnea and Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 23-31.	2.2	15
11	Neuroadrenergic activation in obstructive sleep apnoea syndrome: a new selected meta-analysis - revisited. <i>Journal of Hypertension</i> , 2022, 40, 15-23.	0.5	8
12	Incident aortic root dilatation in the general population: findings from the Pamela study. <i>Journal of Hypertension</i> , 2022, 40, 544-552.	0.5	8
13	Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 137-144.	2.2	1
14	Uric Acid, Hypertensive Phenotypes, and Organ Damage: Data from the Pamela Study. <i>Current Hypertension Reports</i> , 2022, 24, 29-35.	3.5	6
15	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1245-1252.	2.6	15
16	Sympathetic nervous system and hypertension: New evidences. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2022, 238, 102954.	2.8	18
17	White-Coat Hypertension Without Organ Damage: Impact on Long-Term Mortality, New Hypertension, and New Organ Damage. <i>Hypertension</i> , 2022, 79, 1057-1066.	2.7	18
18	Elevated resting heart rate as independent in-hospital prognostic marker in COVID-19. <i>Cardiology Journal</i> , 2022, 29, 181-187.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
20	Endothelial Dysfunction: From a Pathophysiological Mechanism to a Potential Therapeutic Target. <i>Biomedicines</i> , 2022, 10, 78.	3.2	6
21	World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 353-359.	2.2	9
22	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. <i>Hypertension</i> , 2022, 79, 1153-1166.	2.7	20
23	Historical Archive of Blood Pressure and Evolution of Hypertension. <i>Journal of Drug Delivery and Therapeutics</i> , 2022, 12, 215-219.	0.5	0
24	Sympathetic activation and heart rate thresholds for cardiovascular risk in chronic kidney disease. <i>Journal of Hypertension</i> , 2022, 40, 1530-1536.	0.5	8
25	Targeting subclinical organ damage in obstructive sleep apnea: a narrative review. <i>Journal of Human Hypertension</i> , 2021, 35, 26-36.	2.2	18
26	How to unmask masked hypertension: the role of office aortic blood pressure. <i>Hypertension Research</i> , 2021, 44, 256-258.	2.7	2
27	Sympathetic activation in congestive heart failure: an updated overview. <i>Heart Failure Reviews</i> , 2021, 26, 173-182.	3.9	30
28	Monotherapy vs combination treatments of different complexity: a meta-analysis of blood pressure lowering randomized outcome trials. <i>Journal of Hypertension</i> , 2021, 39, 846-855.	0.5	7
29	Hypertension and Periodontitis: An Upcoming Joint Report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 1-3.	2.2	5
30	Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 5-11.	2.2	21
31	Heart rate as a predictor of cardiovascular risk. <i>Minerva Medica</i> , 2021, 112, 130-143.	0.9	11
32	Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases: A Consensus Document by the Italian Society of Hypertension (SIIA). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2021, 28, 85-102.	2.2	15
33	Autonomic Cardiovascular Alterations in Chronic Kidney Disease: Effects of Dialysis, Kidney Transplantation, and Renal Denervation. <i>Current Hypertension Reports</i> , 2021, 23, 10.	3.5	16
34	Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction. <i>Hypertension</i> , 2021, 77, 640-649.	2.7	21
35	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. <i>Clinical Research in Cardiology</i> , 2021, 110, 1073-1082.	3.3	31
36	Coronavirus disease 2019 and cardiovascular complications: focused clinical review. <i>Journal of Hypertension</i> , 2021, 39, 1282-1292.	0.5	62

#	ARTICLE	IF	CITATIONS
37	The UrgeRe (Urgenze Ipertensive: Un Progetto Educazionale Fondato Sulla Vita Reale, Hypertensive) Tj ETQq1 1 0.784314 rgBT /Over bo 2021, 28, 151-157.	2.2	1
38	Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease. Clinical Autonomic Research, 2021, 31, 491-498.	2.5	2
39	Hypertension and COVID-19: Ongoing Controversies. Frontiers in Cardiovascular Medicine, 2021, 8, 639222.	2.4	38
40	Reverse dipping and subclinical cardiac organ damage: a meta-analysis of echocardiographic studies. Journal of Hypertension, 2021, 39, 1505-1512.	0.5	9
41	Predictive Importance of Blood Pressure Characteristics With Increasing Age in Healthy Men and Women. Hypertension, 2021, 77, 1076-1085.	2.7	8
42	Short- and Long-Term Reproducibility of Nighttime Blood Pressure Phenotypes and Nocturnal Blood Pressure Reduction. Hypertension, 2021, 77, 1745-1755.	2.7	11
43	Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 633878.	2.4	10
44	May Measurement Month 2019: an analysis of blood pressure screening results from Italy. European Heart Journal Supplements, 2021, 23, B77-B81.	0.1	4
45	Myocardial strain in hypertension: a meta-analysis of two-dimensional speckle tracking echocardiographic studies. Journal of Hypertension, 2021, 39, 2103-2112.	0.5	24
46	Omega-3 Fatty Acids and Coronary Artery Disease: More Questions Than Answers. Journal of Clinical Medicine, 2021, 10, 2495.	2.4	9
47	Myocardial strain and left ventricular geometry: a meta-analysis of echocardiographic studies in systemic hypertension. Journal of Hypertension, 2021, 39, 2297-2306.	0.5	7
48	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. European Heart Journal, 2021, 42, 2439-2454.	2.2	491
49	The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey. American Journal of Hypertension, 2021, 34, 1247-1254.	2.0	16
50	Clinical Relevance of the Sympatheticâ€“Vascular Interactions in Health and Disease. Biomedicines, 2021, 9, 1007.	3.2	7
51	Blood pressure variability: a new therapeutic target on the horizon. Journal of Hypertension, 2021, 39, 1771-1773.	0.5	5
52	Hypertension and periodontitis: A joint report by the Italian society of hypertension (SIIA) and the Italian society of periodontology and implantology (SIdP). Oral Diseases, 2021, , .	3.0	1
53	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. Frontiers in Cardiovascular Medicine, 2021, 8, 713652.	2.4	18
54	Hypertension and Periodontitis: A Joint Report by the Italian Society of Hypertension (SIIA) and the Italian Society of Periodontology and Implantology (SIdP). High Blood Pressure and Cardiovascular Prevention, 2021, 28, 427-438.	2.2	17

#	ARTICLE	IF	CITATIONS
55	Blood-pressure variability is associated with left-ventricular mechanics in patients with gestational hypertension and preeclampsia. <i>Hypertension Research</i> , 2021, 44, 1625-1632.	2.7	3
56	Sympathetic Neural Mechanisms Underlying Attended and Unattended Blood Pressure Measurement. <i>Hypertension</i> , 2021, 78, 1126-1133.	2.7	13
57	Elevated heart rate and cardiovascular risk in hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1060-1069.	0.5	22
58	Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 178-185.	2.6	24
59	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 62-69.	0.5	49
60	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 333-340.	0.5	46
61	Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 408-416.	0.5	25
62	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 376-380.	0.5	20
63	Limited reliability of heart rate as a sympathetic marker in chronic kidney disease. <i>Journal of Hypertension</i> , 2021, 39, 1429-1434.	0.5	3
64	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. <i>Journal of Hypertension</i> , 2021, 39, 1077-1089.	0.5	44
65	Neuroadrenergic activation in obstructive sleep apnea syndrome: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 2281-2289.	0.5	6
66	Left ventricular mass reduction and hypertrophy regression following renal artery revascularization: a meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 4-11.	0.5	2
67	Targeting persistent normal left ventricular geometry in the general population: a 25-year follow-up study. <i>Journal of Hypertension</i> , 2021, 39, 952-960.	0.5	2
68	Regression of left ventricular hypertrophy in primary aldosteronism after adrenalectomy: a meta-analysis of echocardiographic studies. <i>Journal of Hypertension</i> , 2021, 39, 775-783.	0.5	6
69	Transient effects of carotid baroreflex stimulation via the neck chamber device on central venous pressure. <i>Journal of Clinical Hypertension</i> , 2021, , .	2.0	1
70	The PAMELA research project: a 25-year long journey. <i>Panminerva Medica</i> , 2021, 63, .	0.8	5
71	Introduction to the monographic issue "Recent ongoing epidemiological studies in Italy". <i>Panminerva Medica</i> , 2021, 63, .	0.8	0
72	White-Coat Hypertension: Pathophysiological and Clinical Aspects: Excellence Award for Hypertension Research 2020. <i>Hypertension</i> , 2021, 78, 1677-1688.	2.7	33

#	ARTICLE	IF	CITATIONS
73	Limited reproducibility of MUCH and WUCH: evidence from the ELSA study. <i>European Heart Journal</i> , 2020, 41, 1565-1571.	2.2	38
74	Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. <i>Heart Failure Reviews</i> , 2020, 25, 295-303.	3.9	24
75	Do reverse dippers have the highest risk of right ventricular remodeling?. <i>Hypertension Research</i> , 2020, 43, 213-219.	2.7	9
76	Big data, observational research and P-value: a recipe for false-positive findings? A study of simulated and real prospective cohorts. <i>International Journal of Epidemiology</i> , 2020, 49, 876-884.	1.9	3
77	Left ventricular mass and incident out-of-office hypertension in a general population. <i>Journal of Hypertension</i> , 2020, 38, 633-640.	0.5	1
78	Shades of grey: a matter relevant to sympathetic activity and blood pressure control?. <i>Journal of Hypertension</i> , 2020, 38, 206-207.	0.5	0
79	Targeting Concentric Left Ventricular Hypertrophy in Obstructive Sleep Apnea Syndrome. A Meta-analysis of Echocardiographic Studies. <i>American Journal of Hypertension</i> , 2020, 33, 310-315.	2.0	13
80	Identifying poor cardiorespiratory fitness in overweight and obese children and adolescents by using heart rate variability analysis under resting conditions. <i>Blood Pressure</i> , 2020, 29, 13-20.	1.5	3
81	Left ventricular mass and incident hypertension: Missing pieces in the puzzle. <i>Journal of Clinical Hypertension</i> , 2020, 22, 299-300.	2.0	3
82	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. <i>Hypertension</i> , 2020, 75, 302-308.	2.7	177
83	Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. <i>Journal of Hypertension</i> , 2020, 38, 412-419.	0.5	70
84	Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload. <i>Hypertension</i> , 2020, 76, 1444-1450.	2.7	16
85	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. <i>PLoS ONE</i> , 2020, 15, e0237297.	2.5	51
86	Impact of different dipping patterns on left atrial function in hypertension. <i>Journal of Hypertension</i> , 2020, 38, 2245-2251.	0.5	8
87	Sympathomodulation in congestive heart failure: From drugs to devices. <i>International Journal of Cardiology</i> , 2020, 321, 118-125.	1.7	4
88	Obstructive sleep apnoea syndrome and left ventricular hypertrophy: a meta-analysis of echocardiographic studies. <i>Journal of Hypertension</i> , 2020, 38, 1640-1649.	0.5	17
89	Office and Out-of-Office Blood Pressure Changes Over a Quarter of Century. <i>Hypertension</i> , 2020, 76, 759-765.	2.7	3
90	Is the association between sleep apnea and left ventricular hypertrophy obesity-independent?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1282-1283.	2.0	2

#	ARTICLE	IF	CITATIONS
91	Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020, 38, 1436-1442.	0.5	26
92	Assessment of heart rate as a sympathetic biomarker™: strengths and pitfalls. <i>Journal of Hypertension</i> , 2020, 38, 1460-1461.	0.5	2
93	Impact of heart rate on arterial stiffness: virtual vs. real assessment. <i>Journal of Hypertension</i> , 2020, 38, 2382-2383.	0.5	4
94	Nocturnal blood pressure: the dark side of white-coat hypertension. <i>Journal of Hypertension</i> , 2020, 38, 2404-2408.	0.5	8
95	&lt;p&gt;Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?&lt;/p&gt;. <i>Integrated Blood Pressure Control</i> , 2020, Volume 13, 63-69.	1.2	19
96	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?. <i>Pharmacological Research</i> , 2020, 158, 104906.	7.1	72
97	Sympathetic overdrive in the metabolic syndrome: meta-analysis of published studies. <i>Journal of Hypertension</i> , 2020, 38, 565-572.	0.5	20
98	Age and Multimorbidity Predict Death Among COVID-19 Patients. <i>Hypertension</i> , 2020, 76, 366-372.	2.7	330
99	Association between uric acid and pulse wave velocity in hypertensive patients and in the general population: a systematic review and meta-analysis. <i>Blood Pressure</i> , 2020, 29, 220-231.	1.5	22
100	Heart rate as cardiovascular risk factor. <i>Postgraduate Medicine</i> , 2020, 132, 358-367.	2.0	11
101	Association Between the European Society of Cardiology/European Society of Hypertension Heart Rate Thresholds for Cardiovascular Risk and Neuroadrenergic Markers. <i>Hypertension</i> , 2020, 76, 577-582.	2.7	33
102	The Complex Relationship Between Serum Uric Acid, Endothelial Function and Small Vessel Remodeling in Humans. <i>Journal of Clinical Medicine</i> , 2020, 9, 2027.	2.4	12
103	COVID-19 and arterial hypertension: Hypothesis or evidence?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1120-1126.	2.0	65
104	Does established vascular kidney disease exist?. <i>Journal of Clinical Hypertension</i> , 2020, 22, 296-298.	2.0	5
105	American Versus European Hypertension Guidelines: The Case of White Coat Hypertension. <i>American Journal of Hypertension</i> , 2020, 33, 629-633.	2.0	2
106	Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020, 27, 105-108.	2.2	37
107	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. <i>Journal of Hypertension</i> , 2020, 38, 799-812.	0.5	43
108	Renal denervation in patients with end-stage renal disease and resistant hypertension on long-term haemodialysis. <i>Journal of Hypertension</i> , 2020, 38, 936-942.	0.5	21

#	ARTICLE	IF	CITATIONS
109	Clinical correlates and subclinical cardiac organ damage in different extreme dipping patterns. <i>Journal of Hypertension</i> , 2020, 38, 858-863.	0.5	8
110	Targeting White Coat Hypertension: Is the Daytime Enough?. <i>American Journal of Hypertension</i> , 2020, 33, 703-704.	2.0	1
111	The association between 24-h blood pressure patterns and left ventricular mechanics. <i>Journal of Hypertension</i> , 2020, 38, 282-288.	0.5	18
112	Left ventricular hypertrophy in isolated and dual masked hypertension. <i>Journal of Clinical Hypertension</i> , 2020, 22, 673-677.	2.0	6
113	Microvascular Alterations in Obesity. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 137-147.	0.1	0
114	Secondary Hypertension and Cardiovascular Risk: An Overview. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 197-209.	0.1	1
115	Title is missing!. , 2020, 15, e0237297.		0
116	Title is missing!. , 2020, 15, e0237297.		0
117	Title is missing!. , 2020, 15, e0237297.		0
118	Title is missing!. , 2020, 15, e0237297.		0
119	Title is missing!. , 2020, 15, e0237297.		0
120	Title is missing!. , 2020, 15, e0237297.		0
121	Sympathetic Nerve Traffic and Arterial Baroreflex Function in Apparent Drug-Resistant Hypertension. <i>Hypertension</i> , 2019, 74, 903-909.	2.7	13
122	Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines. <i>Current Hypertension Reports</i> , 2019, 21, 67.	3.5	10
123	Response to: Myocardial fibrosis and arrhythmogenesis in elite athletes. <i>Clinical Cardiology</i> , 2019, 42, 789-790.	1.8	0
124	Pheochromocytoma as a Clinical Model of Peripheral Sympathetic Overdrive: Old and New Findings. <i>Current Hypertension Reports</i> , 2019, 21, 90.	3.5	1
125	Severe systemic cytomegalovirus infection in an immunocompetent patient outside the intensive care unit: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 34.	2.9	5
126	Extreme dipping: More complex than it looks. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1284-1285.	2.0	1



#	ARTICLE	IF	CITATIONS
127	Blood Pressure Non-Dipping and Obstructive Sleep Apnea Syndrome: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1367.	2.4	55
128	Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction. <i>Journal of Hypertension</i> , 2019, 37, 443-448.	0.5	47
129	Exploring the interplay between job strain and different domains of physical activity on the incidence of coronary heart disease in adult men. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1877-1885.	1.8	10
130	Sympathetic Neural Overdrive in the Obese and Overweight State. <i>Hypertension</i> , 2019, 74, 349-358.	2.7	87
131	Pulse wave velocity progression over a medium-term follow-up in hypertensives: Focus on uric acid. <i>Journal of Clinical Hypertension</i> , 2019, 21, 975-983.	2.0	16
132	Renal Denervation Update From the International Sympathetic Nervous System Summit. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3006-3017.	2.8	74
133	The importance of endothelial dysfunction in resistance artery remodelling and cardiovascular risk. <i>Cardiovascular Research</i> , 2019, 116, 429-437.	3.8	20
134	Incident Left Ventricular Hypertrophy in Masked Hypertension. <i>Hypertension</i> , 2019, 74, 56-62.	2.7	19
135	Extreme Dipping: Always Means Nocturnal Hypotension?. <i>American Journal of Hypertension</i> , 2019, 32, 842-847.	2.0	9
136	Left atrial function in elite athletes: A meta-analysis of two-dimensional speckle tracking echocardiographic studies. <i>Clinical Cardiology</i> , 2019, 42, 579-587.	1.8	31
137	Right ventricular mechanics in patients with aortic stenosis and preserved ejection fraction: Is arterial hypertension a new player in the game?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 516-523.	2.0	3
138	Left atrial volume in elite athletes: A meta-analysis of echocardiographic studies. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2019, 29, 922-932.	2.9	9
139	How does blood pressure change in hypertensive patients with atrial fibrillation after successful electrical cardioversion?. <i>Journal of Clinical Hypertension</i> , 2019, 21, 369-371.	2.0	2
140	Neural Mechanisms. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 71-86.	0.1	0
141	Two-Drug Combinations as First-Step Antihypertensive Treatment. <i>Circulation Research</i> , 2019, 124, 1113-1123.	4.5	73
142	Gender-related differences in serum uric acid in treated hypertensive patients from central and east European countries. <i>Journal of Hypertension</i> , 2019, 37, 380-388.	0.5	45
143	Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. <i>Lancet, The</i> , 2019, 394, 2173-2183.	13.7	177
144	Sympathetic neural overdrive in congestive heart failure and its correlates. <i>Journal of Hypertension</i> , 2019, 37, 1746-1756.	0.5	34

#	ARTICLE	IF	CITATIONS
145	Baroreflex activation therapy systems: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2019, 16, 1025-1033.	2.8	14
146	Extreme dipping. <i>Journal of Hypertension</i> , 2019, 37, 1917-1926.	0.5	18
147	The Prognostic Effect of Circadian Blood Pressure Pattern on Long-Term Cardiovascular Outcome Is Independent of Left Ventricular Remodeling. <i>Journal of Clinical Medicine</i> , 2019, 8, 2126.	2.4	12
148	High-normal blood pressure and abnormal left ventricular geometric patterns. <i>Journal of Hypertension</i> , 2019, 37, 1312-1319.	0.5	11
149	Relationships between residual blood pressure variability and cognitive function in the general population of the PAMELA study. <i>Journal of Clinical Hypertension</i> , 2019, 21, 39-45.	2.0	10
150	Response to: Gender differences and the association between right ventricular strain and arterial hypertensionâ€”A commentary. <i>Journal of Clinical Hypertension</i> , 2019, 21, 139-140.	2.0	0
151	High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings From the PAMELA Population. <i>Hypertension</i> , 2019, 73, 612-619.	2.7	48
152	Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2019, 73, 39-41.	2.7	3
153	When Office Blood Pressure Is Not Enough: The Case of Masked Hypertension. <i>American Journal of Hypertension</i> , 2019, 32, 225-233.	2.0	13
154	Pre-hypertension and subclinical carotid damage: a meta-analysis. <i>Journal of Human Hypertension</i> , 2019, 33, 34-40.	2.2	14
155	The European Society of Cardiology (ESC)/European Society of Hypertension (ESH) 2018 guidelines for hypertension diagnosis and treatment: New concepts and recommendations. <i>Pharmacological Research</i> , 2019, 139, 489-490.	7.1	3
156	The Role of the Brain in Neurogenic Prehypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 349-360.	0.1	0
157	Age- and Sex-Specific Reference Values for Media/Lumen Ratio in Small Arteries and Relationship With Risk Factors. <i>Hypertension</i> , 2018, 71, 1193-1200.	2.7	22
158	The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?. <i>Heart Failure Reviews</i> , 2018, 23, 631-639.	3.9	26
159	Carotid intima-media thickness and anti-hypertensive treatment: Focus on angiotensin II receptor blockers. <i>Pharmacological Research</i> , 2018, 129, 20-26.	7.1	5
160	Refractory hypertension focus on nighttime blood pressure and nondipping. <i>Journal of Clinical Hypertension</i> , 2018, 20, 447-449.	2.0	3
161	Right heart remodeling induced by arterial hypertension: Could strain assessment be helpful?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 400-407.	2.0	22
162	Differing associations for sport versus occupational physical activity and cardiovascular risk. <i>Heart</i> , 2018, 104, 1165-1172.	2.9	26

#	ARTICLE	IF	CITATIONS
163	Heart rate as a predictor of cardiovascular risk. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12892.	3.4	64
164	Association Between Atrial, Ventricular and Vascular Morphofunctional Alterations in Rheumatoid Arthritis. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 97-104.	2.2	6
165	Sympathetic and baroreflex abnormalities in the uncomplicated prediabetic state. <i>Journal of Hypertension</i> , 2018, 36, 1195-1200.	0.5	6
166	“Keep an eye” on the heart: retinal microcirculation disarray in congestive heart failure. <i>European Heart Journal</i> , 2018, 39, 57-59.	2.2	5
167	The importance of pulse pressure on cardiovascular risk and total mortality in the general population: Is sex relevant?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1001-1007.	2.0	9
168	Albuminuria and diabetes. <i>Journal of Hypertension</i> , 2018, 36, 1036-1037.	0.5	2
169	Hypertension. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18014.	30.5	636
170	Isolated systolic hypertension in the young. <i>Journal of Hypertension</i> , 2018, 36, 1222-1236.	0.5	61
171	Uric acid and risk of new-onset metabolic syndrome, impaired fasting glucose and diabetes mellitus in a general Italian population. <i>Journal of Hypertension</i> , 2018, 36, 1492-1498.	0.5	61
172	Treatment of hypertension: The ESH/ESC guidelines recommendations. <i>Pharmacological Research</i> , 2018, 128, 315-321.	7.1	73
173	Metabolic syndrome and subclinical carotid damage. <i>Journal of Hypertension</i> , 2018, 36, 23-30.	0.5	19
174	Baroreceptor Stimulation. , 2018, , 1323-1327.		1
175	Determinants of carotid-femoral pulse wave velocity progression in hypertensive patients over a 3.7 years follow-up. <i>Blood Pressure</i> , 2018, 27, 32-40.	1.5	35
176	Hypertensive heart disease beyond left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2018, 36, 744-753.	0.5	15
177	Association of metabolic syndrome with carotid thickening and plaque in the general population: A meta-analysis. <i>Journal of Clinical Hypertension</i> , 2018, 20, 4-10.	2.0	16
178	Risk of new-onset metabolic syndrome associated with white-coat and masked hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1833-1839.	0.5	21
179	Antihypertensive treatment and renal protection: Is there a J-curve relationship?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1560-1574.	2.0	17
180	Night-time heart rate nondipping. <i>Journal of Hypertension</i> , 2018, 36, 1311-1317.	0.5	27

#	ARTICLE	IF	CITATIONS
181	Metoprolol in the treatment of cardiovascular disease: a critical reappraisal. <i>Current Medical Research and Opinion</i> , 2018, 34, 1635-1643.	1.9	11
182	Big Data and Blood Pressure Control: Insights from the PAMELA and BP-CARE Study Cohorts. <i>Current Hypertension Reports</i> , 2018, 20, 82.	3.5	3
183	Monographic issue of pharmacological research on hypertension. <i>Pharmacological Research</i> , 2018, 134, 221-222.	7.1	0
184	Sympathetic Nervous System, Sleep, and Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 74.	3.5	45
185	Does gender affect the association between right ventricular strain and arterial hypertension?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1327-1333.	2.0	6
186	The Sympathetic Nervous System in Hypertension. <i>Contemporary Endocrinology</i> , 2018, , 201-212.	0.1	2
187	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
188	White-Coat Hypertension: the Neglected Subgroup in Hypertension. <i>Korean Circulation Journal</i> , 2018, 48, 552.	1.9	11
189	The norepinephrine transporter deserves more attention. <i>Journal of Hypertension</i> , 2018, 36, 1472-1474.	0.5	1
190	Pre-hypertension and subclinical cardiac damage: A meta-analysis of echocardiographic studies. <i>International Journal of Cardiology</i> , 2018, 270, 302-308.	1.7	20
191	Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. <i>Hypertension</i> , 2018, 72, 483-491.	2.7	79
192	Sex-related relationships between uric acid and target organ damage in hypertension. <i>Journal of Clinical Hypertension</i> , 2018, 20, 193-200.	2.0	36
193	Neurogenic Hypertension. , 2018, , 381-382.		0
194	Treatment of Resistant Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 639-652.	0.1	0
195	Nocturnal Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 663-673.	0.1	0
196	A case of <i>Pseudomonas Aeruginosa</i> commercial tattoo infection. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 301-302.	0.2	2
197	Post-prandial anorexigenic gut peptide, appetite and glucometabolic responses at different eating rates in obese patients undergoing laparoscopic sleeve gastrectomy. <i>Endocrine</i> , 2017, 55, 113-123.	2.3	12
198	Job strain and the incidence of coronary heart diseases: does the association differ among occupational classes? A contribution from a pooled analysis of Northern Italian cohorts. <i>BMJ Open</i> , 2017, 7, e014119.	1.9	18

#	ARTICLE	IF	CITATIONS
199	Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 289-296.	2.2	2
200	Prognostic significance of masked tachycardia in hypertension. Journal of Hypertension, 2017, 35, 468-470.	0.5	1
201	Obesity and hypertension. Pharmacological Research, 2017, 122, 1-7.	7.1	430
202	Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 393-400.	2.2	13
203	Blood pressure control in hypertension. Pros and cons of available treatment strategies. Journal of Hypertension, 2017, 35, 225-233.	0.5	41
204	Short-term blood pressure variability in acute coronary syndrome. Journal of Clinical Hypertension, 2017, 19, 1249-1251.	2.0	3
205	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
206	Effects of serum uric acid on blood-pressure lowering treatment. Current Medical Research and Opinion, 2017, 33, 15-19.	1.9	4
207	Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy. Journal of Hypertension, 2017, 35, 2532-2536.	0.5	28
208	Glucose intolerance as the key risk factor for metabolic syndrome. Journal of Clinical Hypertension, 2017, 19, 848-849.	2.0	1
209	Sympathomodulatory effects of sodium-glucose transporter-2 inhibitors in the kidneys and beyond. Journal of Hypertension, 2017, 35, 1966-1967.	0.5	3
210	Cardiovascular Risk Associated With White-Coat Hypertension. Hypertension, 2017, 70, 668-675.	2.7	37
211	Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: An updated review. Journal of Clinical Hypertension, 2017, 19, 713-721.	2.0	88
212	Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. Nephrology Dialysis Transplantation, 2017, 32, 1351-1356.	0.7	16
213	Effects of renal denervation on short-term blood pressure variability. Journal of Hypertension, 2017, 35, 1780-1781.	0.5	0
214	Endothelin contributes to the blood pressure rise triggered by hypoxia in severe obstructive sleep apnea. Journal of Hypertension, 2017, 35, 118-124.	0.5	9
215	Long-term changes in left ventricular mass echocardiographic findings from a general population. Journal of Hypertension, 2017, 35, 2303-2309.	0.5	5
216	Reliability of heart rate as neuroadrenergic marker in the metabolic syndrome. Journal of Hypertension, 2017, 35, 1685-1690.	0.5	16

#	ARTICLE	IF	CITATIONS
217	Quarter Dose Combination Therapy. <i>Hypertension</i> , 2017, 70, 32-34.	2.7	4
218	Clinical and prognostic value of hypertensive cardiac damage in the PAMELA Study. <i>Hypertension Research</i> , 2017, 40, 329-335.	2.7	17
219	Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. <i>American Journal of Hypertension</i> , 2017, 30, 279-285.	2.0	24
220	Neurohumoral and Endothelial Responses to Heated Water-Based Exercise in Resistant Hypertensive Patients. <i>Circulation Journal</i> , 2017, 81, 339-345.	1.6	28
221	Lercanidipine in the management of hypertension: An update. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2017, 8, 155.	0.4	24
222	Lercanidipine/enalapril combination in the management of obesity-related hypertension. <i>Integrated Blood Pressure Control</i> , 2016, 9, 69.	1.2	2
223	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1678-1688.	0.5	13
224	Device-based treatments in hypertension. <i>Journal of Hypertension</i> , 2016, 34, 1502-1504.	0.5	3
225	Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 838-846.	3.3	22
226	Effects of Renal Denervation on Sympathetic Nervous System Activity. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 303-319.	0.1	0
227	Specific Blood Pressure Targets for Patients With Diabetic Nephropathy?. <i>Diabetes Care</i> , 2016, 39, S228-S233.	8.6	14
228	Threshold and Target for Blood Pressure Lowering in the Elderly. <i>Current Atherosclerosis Reports</i> , 2016, 18, 70.	4.8	4
229	Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study. <i>Advances in Therapy</i> , 2016, 33, 2173-2187.	2.9	7
230	White Coat Hypertension: to Treat or Not to Treat?. <i>Current Hypertension Reports</i> , 2016, 18, 80.	3.5	27
231	The Heterogeneous Nature of White-Coat Hypertension —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2044-2046.	2.8	27
232	Response by Grassi et al to Letter Regarding Article, “The Sympathetic Nervous System Alterations in Human Hypertension” • <i>Circulation Research</i> , 2016, 119, e35-6.	4.5	2
233	New-onset left atrial enlargement in a general population. <i>Journal of Hypertension</i> , 2016, 34, 1838-1845.	0.5	18
234	Response to “Potential Errors and Omissions Related to the Analysis and Conclusions Reported in Cuspidi C, et al • <i>AJH</i> 2014; 27(2):146–156” • <i>American Journal of Hypertension</i> , 2016, 29, 782-783.	2.0	1

#	ARTICLE	IF	CITATIONS
235	Influence of sleep disturbances on age at onset and long-term incidence of major cardiovascular events: the MONICA-Brianza and PAMELA cohort studies. <i>Sleep Medicine</i> , 2016, 21, 126-132.	1.6	23
236	Baroreflex Activation Therapy in Congestive Heart Failure: Novel Findings and Future Insights. <i>Current Hypertension Reports</i> , 2016, 18, 60.	3.5	7
237	Alterations in sympathetic nerve traffic in genetic haemochromatosis before and after iron depletion therapy: a microneurographic study. <i>European Heart Journal</i> , 2016, 37, 988-995.	2.2	10
238	Management of the hypertensive patient with elevated heart rate. <i>Journal of Hypertension</i> , 2016, 34, 813-821.	0.5	116
239	The enigma of obesity-induced hypertension mechanisms in the youth. <i>Journal of Hypertension</i> , 2016, 34, 191-192.	0.5	3
240	Does <scp>QRS</scp> Voltage Correction by Body Mass Index Improve the Accuracy of Electrocardiography in Detecting Left Ventricular Hypertrophy and Predicting Cardiovascular Events in a General Population?. <i>Journal of Clinical Hypertension</i> , 2016, 18, 415-421.	2.0	14
241	Precision medicine should become more "sympathetic"™ in managing hypertension. <i>Journal of Hypertension</i> , 2016, 34, 629-631.	0.5	0
242	Differential effects of enalapril"felodipine versus enalapril"lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 244-251.	2.3	9
243	Sympathomodulatory Effects of Antihypertensive Drug Treatment. <i>American Journal of Hypertension</i> , 2016, 29, 665-675.	2.0	46
244	Sympathetic Nervous System, Hypertension, Obesity and Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 175-179.	2.2	73
245	Evidence for a critical role of the sympathetic nervous system in hypertension. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 457-466.	2.3	138
246	Does skin microcirculation represent a faithful mirror of uric acid alterations?. <i>Journal of Hypertension</i> , 2015, 33, 1531-1532.	0.5	0
247	Natriuretic peptides in the cross-talk of human cardiovascular and metabolic regulation. <i>Journal of Hypertension</i> , 2015, 33, 1139-1141.	0.5	2
248	Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1367-1375.	3.4	140
249	Within-visit BP variability, cardiovascular risk factors, and BP control in central and eastern Europe. <i>Journal of Hypertension</i> , 2015, 33, 2250-2256.	0.5	14
250	Sympathetic nerve traffic and baroreflex function in optimal, normal, and high-normal blood pressure states. <i>Journal of Hypertension</i> , 2015, 33, 1411-1417.	0.5	61
251	Nondipping status and impaired nitroglycerin-mediated vasodilation in resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1533-1535.	0.5	0
252	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. <i>Journal of Hypertension</i> , 2015, 33, 2519-2525.	0.5	40

#	ARTICLE	IF	CITATIONS
253	Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy. <i>Journal of Hypertension</i> , 2015, 33, 346-353.	0.5	20
254	Microvascular function. <i>Journal of Hypertension</i> , 2015, 33, 928-930.	0.5	0
255	Long-term chronic baroreflex activation. <i>Journal of Hypertension</i> , 2015, 33, 1704-1708.	0.5	42
256	New developments in the pathogenesis of obesity-induced hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1499-1508.	0.5	68
257	Risk of mortality in relation to an updated classification of left ventricular geometric abnormalities in a general population. <i>Journal of Hypertension</i> , 2015, 33, 2133-2140.	0.5	34
258	Dual renin-angiotensin system blockade and vascular remodeling. <i>Journal of Hypertension</i> , 2015, 33, 2392-2394.	0.5	1
259	Adverse Prognostic Value of Persistent Office Blood Pressure Elevation in White Coat Hypertension. <i>Hypertension</i> , 2015, 66, 437-444.	2.7	46
260	White Coat Hypertension. , 2015, , .		4
261	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1560-1567.	4.5	11
262	The Sympathetic Nervous System Alterations in Human Hypertension. <i>Circulation Research</i> , 2015, 116, 976-990.	4.5	441
263	Advances in heart rate variability signal analysis: joint position statement by the e-Cardiology ESC Working Group and the European Heart Rhythm Association co-endorsed by the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1341-1353.	1.7	589
264	Carotid Baroreceptor Stimulation in Resistant Hypertension and Heart Failure. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 233-239.	2.2	1
265	White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage. <i>Journal of Hypertension</i> , 2015, 33, 24-32.	0.5	70
266	Blood Pressure Responses to Renal Denervation Precede and Are Independent of the Sympathetic and Baroreflex Effects. <i>Hypertension</i> , 2015, 65, 1209-1216.	2.7	65
267	Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. <i>Blood Pressure Monitoring</i> , 2015, 20, 57-63.	0.8	41
268	Evaluation of the SIGNIFY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1861-1864.	1.8	0
269	Role of Sympathetic Nervous System in the Metabolic Syndrome and Sleep Apnea. , 2015, , 165-175.		1
270	Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan. <i>Blood Pressure</i> , 2015, 24, 55-60.	1.5	71



#	ARTICLE	IF	CITATIONS
271	Untreated Masked Hypertension and Subclinical Cardiac Damage: A Systematic Review and Meta-analysis. <i>American Journal of Hypertension</i> , 2015, 28, 806-813.	2.0	69
272	Neurogenic and Non-neurogenic Mechanisms of White-Coat Hypertension. , 2015, , 51-60.		0
273	Neurohormonal Interactions. , 2015, , 137-150.		1
274	Arterial Alterations in Hypertension. , 2015, , 285-297.		0
275	Similarities and Differences Between Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. <i>Current Vascular Pharmacology</i> , 2014, 12, 63-68.	1.7	8
276	Prognostic Significance of Left Atrial Enlargement in a General Population. <i>Hypertension</i> , 2014, 64, 1205-1211.	2.7	56
277	“Broken” autonomic cardiac circadian clock in obese adolescents: evidence and implications. <i>Clinical Autonomic Research</i> , 2014, 24, 247-248.	2.5	0
278	Long-Term Sympathoinhibitory Effects of Surgically Induced Weight Loss in Severe Obese Patients. <i>Hypertension</i> , 2014, 64, 431-437.	2.7	62
279	Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. <i>International Journal of Cardiology</i> , 2014, 177, 1020-1025.	1.7	93
280	Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. <i>European Journal of Heart Failure</i> , 2014, 16, 977-983.	7.1	152
281	Aggressive Blood Pressure Lowering Is Dangerous: The J-Curve. <i>Hypertension</i> , 2014, 63, 29-36.	2.7	101
282	Relationship Among Morning Blood Pressure Surge, 24-Hour Blood Pressure Variability, and Cardiovascular Outcomes in a White Population. <i>Hypertension</i> , 2014, 64, 943-950.	2.7	66
283	Discovering the sympathomodulatory properties of new calcium channel blockers. <i>Journal of Hypertension</i> , 2014, 32, 1780-1781.	0.5	1
284	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. <i>Journal of Hypertension</i> , 2014, 32, 1741-1750.	0.5	39
285	Evaluation of microvascular structure in humans. <i>Journal of Hypertension</i> , 2014, 32, 2120-2129.	0.5	53
286	Sympathetic activation secondary to chronic kidney disease. <i>Journal of Hypertension</i> , 2014, 32, 1751-1761.	0.5	26
287	Aortic root diameter and risk of cardiovascular events in a general population. <i>Journal of Hypertension</i> , 2014, 32, 1879-1887.	0.5	53
288	Prognostic value of serum uric acid. <i>Journal of Hypertension</i> , 2014, 32, 1237-1244.	0.5	57

#	ARTICLE	IF	CITATIONS
289	Obesity in childhood, ambulatory blood pressure and lifestyle interventions. <i>Journal of Hypertension</i> , 2014, 32, 1397-1399.	0.5	1
290	Role of the Sympathetic Nervous System in Hypertension and Hypertension-Related Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 89-105.	2.2	40
291	The Autonomic Nervous System and Hypertension. <i>Circulation Research</i> , 2014, 114, 1804-1814.	4.5	438
292	Neuroadrenergic disarray in pseudo-resistant and resistant hypertension. <i>Hypertension Research</i> , 2014, 37, 479-483.	2.7	11
293	Reply to the letter "Renal denervation: The potential causes of non-response". <i>International Journal of Cardiology</i> , 2014, 172, 624.	1.7	0
294	Regional differences in sympathetic activation in lean and obese normotensive individuals with obstructive sleep apnoea. <i>Journal of Hypertension</i> , 2014, 32, 383-388.	0.5	22
295	Role of Ambulatory Blood Pressure Monitoring in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 232-237.	3.5	22
296	Neuroadrenergic abnormalities in hypertension and hypertension-related cardiovascular disease. <i>Hypertension Y Riesgo Vascular</i> , 2013, 30, 70-74.	0.6	0
297	Renal denervation in cardiometabolic disease: Concepts, achievements and perspectives. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 77-83.	2.6	17
298	Failure of monolateral renal nerve ablation to exert sympathoinhibitory and blood pressure lowering effects in a patient with resistant hypertension: A case report. <i>International Journal of Cardiology</i> , 2013, 169, e120-e121.	1.7	4
299	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	2.8	124
300	The central sympathetic nervous system in hypertension. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 117, 329-335.	1.8	8
301	Long-Term Prognostic Value of White Coat Hypertension. <i>Hypertension</i> , 2013, 62, 168-174.	2.7	143
302	European and British Guidelines on Hypertension. , 2013, , 433-440.		0
303	Differential patterns of regional neuroadrenergic cardiovascular drive in acromegalic disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2013, 40, 333-337.	1.9	2
304	Sympathetic activation and endothelial dysfunction as therapeutic targets in obesity-related hypertension. <i>Journal of Hypertension</i> , 2013, 31, 259-260.	0.5	3
305	Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People. <i>Diabetes Care</i> , 2013, 36, S292-S300.	8.6	5
306	The "renaissance era"™ of sympathomodulatory interventions in the treatment of hypertension-related congestive heart failure. <i>Journal of Hypertension</i> , 2013, 31, 2133-2135.	0.5	0

#	ARTICLE	IF	CITATIONS
307	Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. <i>Journal of Hypertension</i> , 2013, 31, 2018-2024.	0.5	58
308	Renal nerve ablation as a tool for studying the interactions between arterial stiffness, blood pressure and sympathetic drive. <i>Journal of Hypertension</i> , 2013, 31, 1782-1784.	0.5	2
309	Hypertension-related target organ damage. <i>Journal of Hypertension</i> , 2013, 31, 1083-1085.	0.5	11
310	Muscle and skin sympathetic nerve traffic during physician and nurse blood pressure measurement. <i>Journal of Hypertension</i> , 2013, 31, 1131-1135.	0.5	26
311	Structural Alterations of the Retinal Microcirculation in the "Prehypertensive" High-Normal Blood Pressure State. <i>Current Pharmaceutical Design</i> , 2013, 19, 2375-2381.	1.9	19
312	Home and ambulatory blood pressure in resistant hypertension. <i>EuroIntervention</i> , 2013, 9, R35-R41.	3.2	5
313	The Role of Carotid Baroreceptor Stimulation. , 2013, , 137-144.		0
314	Sympathetic regulation of vascular function in health and disease. <i>Frontiers in Physiology</i> , 2012, 3, 284.	2.8	174
315	Sympathetic nervous system. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 46-51.	2.0	102
316	The TALENT Study. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 607-611.	1.8	0
317	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2012, 30, 1047-1055.	0.5	134
318	The "Sympathetic" Kidney: Multiples Effects of Renal Sympathetic Nerve Ablation. <i>Current Hypertension Reviews</i> , 2012, 8, 250-255.	0.9	0
319	Sometimes you simply have to wait. <i>Journal of Hypertension</i> , 2012, 30, 1111-1113.	0.5	0
320	Normal values of left-ventricular mass. <i>Journal of Hypertension</i> , 2012, 30, 997-1003.	0.5	53
321	ESH Position Paper. <i>Journal of Hypertension</i> , 2012, 30, 837-841.	0.5	227
322	Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension. <i>Journal of Hypertension</i> , 2012, 30, 2066-2073.	0.5	60
323	Insulin"endothelial interactions. <i>Journal of Hypertension</i> , 2012, 30, 673-675.	0.5	0
324	The Sympathetic Nervous System and New Nonpharmacologic Approaches to Treating Hypertension: A Focus on Renal Denervation. <i>Canadian Journal of Cardiology</i> , 2012, 28, 311-317.	1.7	25

#	ARTICLE	IF	CITATIONS
325	Evaluation of the ASPIRANT trial. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2573-2577.	1.8	1
326	Novel Antihypertensive Therapies: Renal Sympathetic Nerve Ablation and Carotid Baroreceptor Stimulation. <i>Current Hypertension Reports</i> , 2012, 14, 567-572.	3.5	10
327	Total Cardiovascular Risk, Blood Pressure Variability and Adrenergic Overdrive in Hypertension: Evidence, Mechanisms and Clinical Implications. <i>Current Hypertension Reports</i> , 2012, 14, 333-338.	3.5	74
328	Sympatho-Vagal Imbalance in Hypertension. , 2012, , 345-348.		3
329	Blood Pressure Control and Antihypertensive Treatment. <i>Current Vascular Pharmacology</i> , 2012, 10, 506-511.	1.7	5
330	New therapeutic approaches for resistant hypertension. <i>Journal of Nephrology</i> , 2012, 25, 276-281.	2.0	11
331	Resistant Hypertension: Epidemiological and Evolving Therapeutic Concepts. , 2012, , 25-32.		0
332	Impact of new clinical trials on recent guidelines on hypertension management. <i>Annals of Medicine</i> , 2011, 43, 124-132.	3.8	7
333	The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2421-2424.	1.8	5
334	Sympathoinhibitory effects of statins in chronic kidney disease. <i>Journal of Hypertension</i> , 2011, 29, 2064-2067.	0.5	3
335	European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. <i>Journal of Hypertension</i> , 2011, 29, 189-193.	0.5	11
336	Association between ADRA1A gene and the metabolic syndrome: candidate genes and functional counterpart in the PAMELA population. <i>Journal of Hypertension</i> , 2011, 29, 1121-1127.	0.5	18
337	Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. <i>European Heart Journal</i> , 2011, 32, 218-225.	2.2	70
338	Sympathetic Mechanisms, Organ Damage, and Antihypertensive Treatment. <i>Current Hypertension Reports</i> , 2011, 13, 303-308.	3.5	44
339	Prevention of Microalbuminuria in Diabetes Mellitus: Results of the ROADMAP Trial. <i>Current Hypertension Reports</i> , 2011, 13, 265-267.	3.5	2
340	The ACQUIRE trial. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1665-1667.	1.8	1
341	Selective endothelin receptor blockade in resistant hypertension: results of the DORADO trial. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 153-155.	1.8	7
342	Cardiovascular consequences of poor compliance to antihypertensive therapy. <i>Blood Pressure</i> , 2011, 20, 196-203.	1.5	11

#	ARTICLE	IF	CITATIONS
343	Diagnosis and management of patients with white-coat and masked hypertension. <i>Nature Reviews Cardiology</i> , 2011, 8, 686-693.	13.7	75
344	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2620-2627.	4.5	46
345	Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal Failure. <i>Hypertension</i> , 2011, 57, 846-851.	2.7	268
346	A lesson from polycystic ovarian syndrome: untangling the role of renal sympathetic nervous system on hypertension and insulin resistance. <i>Journal of Hypertension</i> , 2011, 29, 836-837.	0.5	3
347	The morning blood pressure surge. <i>Journal of Hypertension</i> , 2011, 29, 2316-2319.	0.5	5
348	Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events. <i>Journal of Hypertension</i> , 2010, 28, 999-1006.	0.5	60
349	Impact of the metabolic syndrome on subcutaneous microcirculation in obese patients. <i>Journal of Hypertension</i> , 2010, 28, 1708-1714.	0.5	30
350	The effects of sex and method of blood pressure measurement on genetic associations with blood pressure in the PAMELA study. <i>Journal of Hypertension</i> , 2010, 28, 465-477.	0.5	32
351	The "Curve" Problem Revisited: Old and New Findings. <i>Current Hypertension Reports</i> , 2010, 12, 290-295.	3.5	18
352	Structural and Functional Alterations of Subcutaneous Small Resistance Arteries in Severe Human Obesity. <i>Obesity</i> , 2010, 18, 92-98.	3.0	98
353	The "neuroadrenergic hypothesis" in hypertension: current evidence. <i>Experimental Physiology</i> , 2010, 95, 581-586.	2.0	135
354	Management of essential hypertension. <i>British Medical Bulletin</i> , 2010, 94, 189-199.	6.9	17
355	Sympathetic Activation in Obesity. <i>Hypertension</i> , 2010, 56, 338-340.	2.7	21
356	Sympathetic Neural Activity in Hypertension and Related Diseases. <i>American Journal of Hypertension</i> , 2010, 23, 1052-1060.	2.0	203
357	Indices of sympathetic activity and the paradox of chromogranin A. <i>Journal of Hypertension</i> , 2010, 28, 676-678.	0.5	4
358	Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander?. <i>Journal of Hypertension</i> , 2010, 28, 1809-1810.	0.5	8
359	Diurnal blood pressure variation and sympathetic activity. <i>Hypertension Research</i> , 2010, 33, 381-385.	2.7	89
360	Blood pressure control in resistant hypertension: new therapeutic options. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1579-1585.	1.5	8

#	ARTICLE	IF	CITATIONS
361	Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea. <i>Journal of Hypertension</i> , 2010, 28, 1313-1320.	0.5	41
362	Impaired Autonomic Blood Pressure and Blood Volume Control in Chronic Renal Failure. , 2010, , 291-297.		0
363	Prevalence of cardiovascular risk factors in an unselected Italian population. <i>Acta Cardiologica</i> , 2009, 64, 771-778.	0.9	8
364	Sympathetic and Baroreflex Cardiovascular Control in Hypertension-Related Left Ventricular Dysfunction. <i>Hypertension</i> , 2009, 53, 205-209.	2.7	157
365	Long-Term Risk of Sustained Hypertension in White-Coat or Masked Hypertension. <i>Hypertension</i> , 2009, 54, 226-232.	2.7	258
366	Response to Possible Difference in the Sympathetic Activation on Extreme Dippers With or Without Exaggerated Morning Surge. <i>Hypertension</i> , 2009, 53, .	2.7	0
367	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. <i>Journal of Hypertension</i> , 2009, 27, 2121-2158.	0.5	1,236
368	Assessment of Sympathetic Cardiovascular Drive in Human Hypertension. <i>Hypertension</i> , 2009, 54, 690-697.	2.7	316
369	Heart Rate, Sympathetic Cardiovascular Influences, and The Metabolic Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 31-37.	3.1	69
370	Antihypertensive treatment and stroke prevention: From recent meta-analyses to the PROFESS trial. <i>Current Hypertension Reports</i> , 2009, 11, 265-270.	3.5	6
371	Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 469-475.	2.6	19
372	Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1446-1451.	3.4	19
373	Metabolic syndrome and cardiometabolic risk: An update. <i>Blood Pressure</i> , 2009, 18, 7-16.	1.5	15
374	Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?. <i>Journal of Hypertension</i> , 2009, 27, 1341-1349.	0.5	53
375	Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. <i>Journal of Hypertension</i> , 2009, 27, 2458-2464.	0.5	144
376	Behaviour of regional adrenergic outflow in mild-to-moderate renal failure. <i>Journal of Hypertension</i> , 2009, 27, 562-566.	0.5	24
377	European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. <i>Journal of Hypertension</i> , 2009, 27, 207-211.	0.5	37
378	When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. <i>Journal of Hypertension</i> , 2009, 27, 923-934.	0.5	243

#	ARTICLE	IF	CITATIONS
379	Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. <i>Journal of Hypertension</i> , 2009, 27, 1672-1678.	0.5	95
380	Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications. <i>Current Vascular Pharmacology</i> , 2009, 7, 137-145.	1.7	36
381	Implementation of new evidence into hypertension guidelines: the case of the ONTARGET and TRANSCEND trials. <i>Journal of Hypertension</i> , 2009, 27, S40-S44.	0.5	4
382	Phosducin " a candidate gene for stress-dependent hypertension. <i>Journal of Clinical Investigation</i> , 2009, 119, 3515-8.	8.2	8
383	Sympathetic activation in cardiovascular and renal disease. <i>Journal of Nephrology</i> , 2009, 22, 190-5.	2.0	26
384	Essential hypertension and the sympathetic nervous system. <i>Neurological Sciences</i> , 2008, 29, 33-36.	1.9	44
385	Management of very elderly hypertensives: the HYVET study. <i>Aging Clinical and Experimental Research</i> , 2008, 20, 494-495.	2.9	6
386	The Clinical Significance of Blood Pressure Lowering Treatment: Is First-Line Drug Choice Important?. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008, 15, 117-119.	2.2	0
387	Adrenergic, Metabolic, and Reflex Abnormalities in Reverse and Extreme Dipper Hypertensives. <i>Hypertension</i> , 2008, 52, 925-931.	2.7	178
388	Sympathetic activation in congestive heart failure: Reproducibility of neuroadrenergic markers. <i>European Journal of Heart Failure</i> , 2008, 10, 1186-1191.	7.1	39
389	Editorial. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 5-12.	2.1	25
390	Review: Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2008, 9, 66-74.	1.7	13
391	Heart rate as a sympathetic marker during acute adrenergic challenge. <i>Journal of Hypertension</i> , 2008, 26, 70-75.	0.5	14
392	Impaired baroreflex sensitivity as a potential marker of cardiovascular risk in hypertension. <i>Journal of Hypertension</i> , 2008, 26, 1303-1304.	0.5	17
393	Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. <i>Journal of Hypertension</i> , 2008, 26, 1602-1611.	0.5	56
394	Multiple sampling improves norepinephrine reproducibility in essential hypertension: a comparison with the microneurographic technique. <i>Journal of Hypertension</i> , 2008, 26, 2185-2190.	0.5	6
395	Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic Syndrome. <i>Hypertension</i> , 2007, 49, 535-541.	2.7	117
396	Blood pressure lowering effects of non-surgical procedures for vascular decompression: good news to be taken with caution. <i>Journal of Human Hypertension</i> , 2007, 21, 341-342.	2.2	1

#	ARTICLE	IF	CITATIONS
397	Response to Sympathetic Activity, Heart Failure, Obesity, and Metabolic Syndrome: Is There Any Role for Sleep Apnea?. Hypertension, 2007, 49, .	2.7	0
398	Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation?. Journal of Hypertension, 2007, 25, 47-49.	0.5	10
399	Long-Term Prognostic Value of Blood Pressure Variability in the General Population. Hypertension, 2007, 49, 1265-1270.	2.7	329
400	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.5	4,778
401	Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Hypertension, 2007, 49, 40-47.	2.7	221
402	Neurogenic Abnormalities in Masked Hypertension. Hypertension, 2007, 50, 537-542.	2.7	121
403	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762.	0.5	1,152
404	The sympathetic nervous system and the metabolic syndrome. Journal of Hypertension, 2007, 25, 909-920.	0.5	318
405	2007 ESH-ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232.	1.5	292
406	The PAMELA (Pressioni Arteriose Monitorate E Loro Associazioni) Study. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 83-88.	2.2	3
407	Hyperadrenergic and Labile Hypertension. , 2007, , 719-726.		5
408	Blood pressure control and therapeutic modulation of the adrenergic overdrive. Current Hypertension Reports, 2007, 9, 167-169.	3.5	1
409	Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Current Hypertension Reports, 2007, 9, 299-304.	3.5	11
410	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	2.2	1,617
411	Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Pressure, 2006, 15, 268-274.	1.5	6
412	Sympathetic Overdrive and Cardiovascular Risk in the Metabolic Syndrome. Hypertension Research, 2006, 29, 839-847.	2.7	118
413	Reviewer Critique of the Sympathetic Drive After Acute Myocardial Infarction in Hypertensive Patients. American Journal of Hypertension, 2006, 19, 1077-1078.	2.0	0
414	New-onset diabetes and antihypertensive drugs. Journal of Hypertension, 2006, 24, 3-10.	0.5	242



#	ARTICLE	IF	CITATIONS
415	Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. <i>Journal of Hypertension</i> , 2006, 24, 603-610.	0.5	175
416	Angiotensinâ€“sympathetic system interactions in cardiovascular and metabolic disease. <i>Journal of Hypertension</i> , 2006, 24, S51-S56.	0.5	56
417	Baroreflex Function in Hypertension: Consequences for Antihypertensive Therapy. <i>Progress in Cardiovascular Diseases</i> , 2006, 48, 407-415.	3.1	46
418	Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure. <i>Hypertension</i> , 2006, 47, 846-853.	2.7	613
419	Angiotensin II as the link between nitric oxide and neuroadrenergic function. <i>Journal of Hypertension</i> , 2005, 23, 935-937.	0.5	14
420	Obesity and vascular stiffness: when body fat has an adverse impact on arterial dynamics. <i>Journal of Hypertension</i> , 2005, 23, 1789-1791.	0.5	13
421	Intermediate versus hard end points in clinical trials on hypertension. <i>Current Hypertension Reports</i> , 2005, 7, 294-297.	3.5	4
422	Relationship of Office, Home, and Ambulatory Blood Pressure to Blood Glucose and Lipid Variables in the PAMELA Population. <i>Hypertension</i> , 2005, 45, 1072-1077.	2.7	99
423	Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population. <i>Circulation</i> , 2005, 111, 1777-1783.	1.6	896
424	Obstructive Sleep Apneaâ€“Dependent and â€“Independent Adrenergic Activation in Obesity. <i>Hypertension</i> , 2005, 46, 321-325.	2.7	196
425	Assessment of 24-h neuroadrenergic profile: does the dream come true?. <i>Journal of Hypertension</i> , 2005, 23, 1137-1139.	0.5	0
426	Sympathetic Drive as a Determinant of Weight Loss Intervention Outcome Strengths and Limitations. <i>American Journal of Hypertension</i> , 2005, 18, 1517-1518.	2.0	1
427	Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs. <i>Current Pharmaceutical Design</i> , 2004, 10, 3579-3589.	1.9	44
428	Neurogenic Hypertension: Is the Enigma of Its Origin Near the Solution?. <i>Hypertension</i> , 2004, 43, 154-155.	2.7	28
429	Sustained Sympathoinhibitory Effects of Cardiac Resynchronization Therapy in Severe Heart Failure. <i>Hypertension</i> , 2004, 44, 727-731.	2.7	44
430	Cardiovascular and sympathetic effects of reversing insulin resistance in hypertension. <i>Journal of Hypertension</i> , 2004, 22, 1671-1672.	0.5	5
431	Leptin, sympathetic nervous system, and baroreflex function. <i>Current Hypertension Reports</i> , 2004, 6, 236-240.	3.5	49
432	Sympathetic and baroreflex function in hypertensive or heart failure patients with ventricular arrhythmias. <i>Journal of Hypertension</i> , 2004, 22, 1747-1753.	0.5	28

#	ARTICLE	IF	CITATIONS
433	Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. <i>Journal of Hypertension</i> , 2004, 22, 2363-2369.	0.5	271
434	Effects of the Combination of Low-Dose Nifedipine GITS 20 mg and Losartan 50 mg in Patients with Mild to Moderate Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 300-305.	1.9	22
435	Neuroadrenergic effects of calcium channel blockers. <i>Journal of Hypertension</i> , 2004, 22, 887-888.	0.5	8
436	Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. <i>Journal of Hypertension</i> , 2004, 22, 2387-2396.	0.5	50
437	Counteracting the sympathetic nervous system in essential hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 513-519.	2.0	77
438	Aging, physical fitness and endothelial function: are all ultracentenarians marathon runners?. <i>Clinical Science</i> , 2004, 106, 239-240.	4.3	2
439	Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: Rationale and options. <i>Current Hypertension Reports</i> , 2003, 5, 277-280.	3.5	21
440	Behaviour of the adrenergic cardiovascular drive in atrial fibrillation and cardiac arrhythmias. <i>Acta Physiologica Scandinavica</i> , 2003, 177, 399-404.	2.2	37
441	Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: Results of a double-blind randomized multicentre trial. <i>Blood Pressure</i> , 2003, 12, 35-40.	1.5	44
442	Impairment of Thermoregulatory Control of Skin Sympathetic Nerve Traffic in the Elderly. <i>Circulation</i> , 2003, 108, 729-735.	1.6	80
443	Short-Versus Long-Term Effects of Different Dihydropyridines on Sympathetic and Baroreflex Function in Hypertension. <i>Hypertension</i> , 2003, 41, 558-562.	2.7	54
444	Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients. <i>Hypertension</i> , 2003, 42, 873-877.	2.7	95
445	Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals. <i>Journal of Hypertension</i> , 2003, 21, 1761-1769.	0.5	202
446	Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. <i>Blood Pressure Supplement</i> , 2003, 2, 35-40.	0.2	18
447	Blood Pressure Variability and Organ Damage in a General Population. <i>Hypertension</i> , 2002, 39, 710-714.	2.7	261
448	Sympathetic Response to Ventricular Extrasystolic Beats in Hypertension and Heart Failure. <i>Hypertension</i> , 2002, 39, 886-891.	2.7	28
449	Prevalence of Left Ventricular Hypertrophy in Hypertensive Patients Without and With Blood Pressure Control. <i>Hypertension</i> , 2002, 39, 744-749.	2.7	104
450	Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension. <i>Circulation</i> , 2002, 106, 1957-1961.	1.6	126

#	ARTICLE	IF	CITATIONS
451	Systolic and diastolic blood pressure control in antihypertensive drug trials. <i>Journal of Hypertension</i> , 2002, 20, 1461-1464.	0.5	233
452	Systolic vs Diastolic Blood Pressure Control in the Hypertensive Patients of the PAMELA Population. <i>Archives of Internal Medicine</i> , 2002, 162, 582.	3.8	97
453	Secondary prevention of stroke: Old and new evidence. <i>Aging Clinical and Experimental Research</i> , 2002, 14, 216-220.	2.9	5
454	Systolic blood pressure: an underestimated cardiovascular risk factor. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 2002, 20, S21-7.	0.1	14
455	Defining ambulatory and home blood pressure normality: further considerations based on data from the PAMELA study. <i>Journal of Hypertension</i> , 2001, 19, 995-999.	0.5	40
456	Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. <i>Journal of Hypertension</i> , 2001, 19, 1713-1716.	0.5	67
457	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141-146.	4.3	45
458	Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. <i>Clinical Science</i> , 2001, 101, 141.	4.3	15
459	Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. <i>Hepatology</i> , 2001, 34, 1113-1118.	7.3	35
460	Effects of Chronic Clonidine Administration on Sympathetic Nerve Traffic and Baroreflex Function in Heart Failure. <i>Hypertension</i> , 2001, 38, 286-291.	2.7	31
461	Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. <i>Journal of Hypertension</i> , 2000, 18, 587-593.	0.5	83
462	Adrenergic and Reflex Abnormalities in Obesity-Related Hypertension. <i>Hypertension</i> , 2000, 36, 538-542.	2.7	259
463	Mechanisms and Clinical Implications of Blood Pressure Variability. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 35, S15-S19.	1.9	90
464	Muscle and Skin Sympathetic Nerve Traffic During the "White-Coat" Effect. <i>Circulation</i> , 1999, 100, 222-225.	1.6	91
465	Sympathetic Nerve Traffic Responses to Surgical Removal of Pheochromocytoma. <i>Hypertension</i> , 1999, 34, 461-465.	2.7	38
466	Effects of Amlodipine on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. <i>Hypertension</i> , 1999, 33, 671-675.	2.7	19
467	Sympathetic Activation in the Pathogenesis of Hypertension and Progression of Organ Damage. <i>Hypertension</i> , 1999, 34, 724-728.	2.7	428
468	How to assess sympathetic activity in humans. <i>Journal of Hypertension</i> , 1999, 17, 719-734.	0.5	383

#	ARTICLE	IF	CITATIONS
469	Dissociation Between Muscle and Skin Sympathetic Nerve Activity in Essential Hypertension, Obesity, and Congestive Heart Failure. <i>Hypertension</i> , 1998, 31, 64-67.	2.7	228
470	Baroreflex Control of Sympathetic Nerve Activity in Essential and Secondary Hypertension. <i>Hypertension</i> , 1998, 31, 68-72.	2.7	443
471	Body Weight Reduction, Sympathetic Nerve Traffic, and Arterial Baroreflex in Obese Normotensive Humans. <i>Circulation</i> , 1998, 97, 2037-2042.	1.6	321
472	Seasonal variations in home and ambulatory blood pressure in the PAMELA population. <i>Journal of Hypertension</i> , 1998, 16, 1585-1592.	0.5	175
473	Heart rate as marker of sympathetic activity. <i>Journal of Hypertension</i> , 1998, 16, 1635-1639.	0.5	231
474	Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. <i>Journal of Hypertension</i> , 1998, 16, 1789-1796.	0.5	70
475	Role of the sympathetic nervous system in human hypertension. <i>Journal of Hypertension</i> , 1998, 16, 1979-1987.	0.5	231
476	Comparison between Reproducibility and Sensitivity of Muscle Sympathetic Nerve Traffic and Plasma Noradrenaline in Man. <i>Clinical Science</i> , 1997, 92, 285-289.	4.3	114
477	Combination treatment in antihypertensive drug trials. , 1997, 11, 517-518.		8
478	Left Ventricular Hypertrophy and Sympathetic Activity. <i>Advances in Experimental Medicine and Biology</i> , 1997, 432, 173-179.	1.6	9
479	Effects of Chronic ACE Inhibition on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. <i>Circulation</i> , 1997, 96, 1173-1179.	1.6	173
480	Baroreflex Impairment by Low Sodium Diet in Mild or Moderate Essential Hypertension. <i>Hypertension</i> , 1997, 29, 802-807.	2.7	51
481	Ambulatory and Home Blood Pressure Normality in the Elderly. <i>Hypertension</i> , 1997, 30, 1-6.	2.7	131
482	Baroreceptor Control of the Circulation in Man. An Update. <i>Clinical and Experimental Hypertension</i> , 1995, 17, 387-397.	1.3	17
483	Sympathetic Activation and Loss of Reflex Sympathetic Control in Mild Congestive Heart Failure. <i>Circulation</i> , 1995, 92, 3206-3211.	1.6	351
484	Sympathetic Activation in Obese Normotensive Subjects. <i>Hypertension</i> , 1995, 25, 560-563.	2.7	472
485	Sympathetic Modulation of Radial Artery Compliance in Congestive Heart Failure. <i>Hypertension</i> , 1995, 26, 348-354.	2.7	86
486	Radial Artery Compliance in Young, Obese, Normotensive Subjects. <i>Hypertension</i> , 1995, 26, 984-988.	2.7	38

#	ARTICLE	IF	CITATIONS
487	Evaluating sympathetic activity in human hypertension. Journal of Hypertension, 1993, 11, S13-S19.	0.5	13
488	Sympathomoderating influence of benazepril in essential hypertension. Journal of Hypertension, 1992, 10, 373-378.	0.5	24
489	Cardiopulmonary receptor regulation of renin release. American Journal of Medicine, 1988, 84, 97-104.	1.5	36
490	Effects of Celiprolol on Reflex Control of the Cardiovascular System in Essential Hypertension. Journal of Cardiovascular Pharmacology, 1986, 8, S67-S74.	1.9	35